 Athenex Inc NASDAQ: ATNX announced data presentation from a Phase 1 study evaluating encequidar Oral Paclitaxel in combination with Merck Co Incs NYSE: MRK Keytruda pembrolizumab in advanced solid malignancies. Paclitaxel is one of the most commonly used chemotherapies. 